Pranoprofen combined Flumetholon for severe dry eye:an analysis of 106 cases

Objective To evaluate the clinical efficacy of Pranoprofen combined Flumetholon in treatment of severe dry eye. Methods Two hundred and twelve patients with severe dry eye were randomly divided into two groups by random number method with 106 cases in each group.The control group was administrated with Flumetholon,while the observation group with additional Pranoprofen based on the treatment in the control group.Before and after the treatment,the SPEED score for dry eye symptoms,fluorescein staining (FLS) score,tear film break-up time (BUT),Schirmer test (SchirmerⅠ),levels of inflammatory cytokines indicators[interleukin-6(IL-6),interleukin-10(IL-10),tumor necrosis factor α(TNF-α)]of the two groups were tested,and the efficacy of the two groups were compared. Results After the treatment,SPEED score,FLS scores of both groups were significantly reduced (P<0.05),and the SPEED score,FLS scores of the observation group were significantly lower than those of the control group (P<0.05).After the treatment,BUT and SchirmerⅠof both groups were significantly increased (P<0.05),and those of the observation group were significantly higher than those of the control group (P<0.05).After the treatment,levels of IL-6,IL-10 and TNF-α of the two groups were significantly reduced (P<0.05),and those of the observation group were significantly lower than those of the control group (P<0.05).After the treatment,the total effective rate of the observation group was 90.6%,which was significantly higher than that of the control group (77.4%),P<0.05.After the treatment,the incidence of adverse reactions of the observation group was 5.7%,which was significantly lower than 14.2% in the control group (P<0.05). Conclusion For the severe dry eye patients,Pranoprofen combined Flumetholon can effectively improve the symptoms,enhance tear film stability,and reduce the ocular surface damage,with satisfaction efficacy.